Pfizer is terminating a late-stage trial assessing Inlyta in patients at risk of kidney cancer recurrence after an interim analysis showed that it was highly unlikely the drug would offer any benefit in this setting.
Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures.
It is looking likely that another late-stage candidate for Alzheimer’s disease will fail to make it past Phase III trials, with vTv Therapeutics’ experimental therapy the latest in a long line to miss its targets.
European regulators have expanded the scope of Sobi’s Kineret to include the treatment of Still’s disease, a rare, systemic, multi-organ, auto-inflammatory disorder that affects around 25,000 children and adults in the EU.
MSD’s Keytruda has significantly increased overall survival in patients with lung cancer expressing any level of PD-L1 when used as monotherapy in the first-line setting, potentially significantly increasing the drug’s treatment scope.